Sanofi (SNY) Non-Current Deferred Tax Liability (2009 - 2026)

Sanofi has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $1.8 billion for Q2 2026.

• In Q2 2026, Non-Current Deferred Tax Liability fell 7.01% year-over-year to $1.8 billion; the TTM figure through Jun 2026 stood at $1.8 billion (down 7.01% YoY), while the FY2025 annual figure was $1.9 billion, down 17.28% from the prior year.
• Non-Current Deferred Tax Liability came in at $1.8 billion for Q2 2026 at Sanofi, down from $1.9 billion in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.3 billion in Q4 2024 to a low of $1.7 billion in Q2 2022.
• Average Non-Current Deferred Tax Liability over 5 years is $2.0 billion, with a median of $1.9 billion recorded in 2025.
• Year-over-year, Non-Current Deferred Tax Liability slipped 17.96% in 2022 and increased 28.38% in 2023.
• Over 5 years, Non-Current Deferred Tax Liability stood at $1.9 billion in 2022, then rose by 6.38% to $2.0 billion in 2023, then climbed by 15.84% to $2.3 billion in 2024, then dropped by 16.21% to $1.9 billion in 2025, then decreased by 6.92% to $1.8 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $1.8 billion in Q2 2026, $1.9 billion in Q4 2025, and $1.9 billion in Q2 2025.